| Bear Paw Hospice 30 W 13th St, Havre, MT, 59501 | |
| (406) 262-1444 |
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| Name | Bear Paw Hospice |
|---|---|
| Location | 30 W 13th St, Havre, Montana |
| Hospice ID | 271516 |
| Category | Part of a hospital |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| SSA county code | 200 |
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| NPI Number | 1952374183 |
| Organization Name | Northern Montana Hospital |
| Address | 30 13th St Havre, Montana, 59501 |
| Phone Number | (406)262-1302 |
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 90.9 | 93.3 |
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| Home Health Aides | 0.2 |
| Medical Social Workers | 0.4 |
| Physicians | 0.01 |
| Registered Nurses | 1.5 |
| Other Personnel | 1 |
| Total Employees | 3.11 |
|---|
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| Home Health Aides | 0.06 |
| Total Volunteers | 0.06 |
|---|
News Archive
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
Autism may be more common worldwide than previously thought, according to researchers from the George Washington University and Yale University.
More than 80 per cent of oral health patients are willing to receive rapid HIV-testing in dental settings, which could help reduce the spread of the HIV according to a groundbreaking study revealed today at a Sydney University HIV Testing Symposium.
› Verified 4 days ago
| Bear Paw Hospice Location: 30 W 13th St, Havre, Montana, 59501 Phone: (406) 262-1444 |